<SEC-DOCUMENT>0000950170-24-140393.txt : 20241226
<SEC-HEADER>0000950170-24-140393.hdr.sgml : 20241226
<ACCEPTANCE-DATETIME>20241226160231
ACCESSION NUMBER:		0000950170-24-140393
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20241223
FILED AS OF DATE:		20241226
DATE AS OF CHANGE:		20241226

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Keson-Brookes Maiken
		CENTRAL INDEX KEY:			0001693805
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41837
		FILM NUMBER:		241581027

	MAIL ADDRESS:	
		STREET 1:		35 OAK HILL ROAD
		CITY:			FAYVILLE
		STATE:			MA
		ZIP:			01745

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mural Oncology plc
		CENTRAL INDEX KEY:			0001971543
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380
		BUSINESS PHONE:		353 1 905 8020

	MAIL ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mural Oncology Ltd
		DATE OF NAME CHANGE:	20230403

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pistachiovale Ltd
		DATE OF NAME CHANGE:	20230329
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-12-23</periodOfReport>

    <issuer>
        <issuerCik>0001971543</issuerCik>
        <issuerName>Mural Oncology plc</issuerName>
        <issuerTradingSymbol>MURA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001693805</rptOwnerCik>
            <rptOwnerName>Keson-Brookes Maiken</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MURAL ONCOLOGY PLC</rptOwnerStreet1>
            <rptOwnerStreet2>10 EARLSFORT TERRACE</rptOwnerStreet2>
            <rptOwnerCity>DUBLIN 2</rptOwnerCity>
            <rptOwnerState>L2</rptOwnerState>
            <rptOwnerZipCode>D02 T380</rptOwnerZipCode>
            <rptOwnerStateDescription>IRELAND</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>true</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2024-12-23</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>2555</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.27</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>41295</value>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024.</footnote>
        <footnote id="F2">The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F3">Includes 38,705 unvested restricted stock units.</footnote>
    </footnotes>

    <remarks>Chief Legal Officer and Secretary</remarks>

    <ownerSignature>
        <signatureName>/s/ Maiken Keson-Brookes</signatureName>
        <signatureDate>2024-12-26</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
